Randomized Phase II Trial of Postoperative Radiotherapy With Concurrent JS001 PD-1 Antibody vs. Postoperative Radiotherapy Alone in Intermediate/High-risk Head and Neck Cancer Patients With a Contraindication to Cisplatin
Latest Information Update: 10 Jul 2024
At a glance
- Drugs Toripalimab (Primary)
- Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms IMPORT
- 04 Jun 2024 Results (n=87; Between September 2020 and May 2023) assessing the survival outcomes of concurrent radiotherapy and toripalimab versus radiotherapy alone for elderly patients with postoperative head and neck squamous cell carcinoma unfit for cisplatin, presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
- 07 Jun 2022 Results (n=38) assessing feasibility and quality of life of postoperative concurrent radiotherapy and toripalimab in elderly patients with head and neck squamous cell carcinoma, presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 27 Aug 2020 New trial record